Good, Bad, or Indifferent on Drug Pricing: A Value Benchmark Approach for Newly Launched Drugs in the United States.
Swarali Tadwalker, MPH Hardly a day goes by without a new article being published in the mainstream press [...]
Removing Bias from HEOR: Standardizing the Costs of Adverse Events
By Jim Davis What are the total costs of prescribing a particular drug? At its core, all health [...]
21st Century Cures and Off-Label Promotion Benefit HEOR and Drug Safety
By Jim Davis As my writing for the AdverseEvents Blog can attest, I’m in favor of data transparency. [...]
WHEN 1+1=3: HOW ELECTRONIC HEALTH RECORDS AND CLAIMS CAN BE USED SYNERGISTICALLY
Sponsored blog posting by DaVita Clinical Research. 1. Combining Drug Development with Real-World Data Analytics DaVita Clinical Research® (DCR®), a [...]
Advertisement
